Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Annals of Surgical Oncology|June 26, 2023
Hyperthermic Intraperitoneal Chemotherapy in Ovarian CancerJulia H Gelissen, Naomi N Adjei, Blair McNamara, et al.
Gynecologic Oncology|March 16, 2024
Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancerBlair McNamara, Cem Demirkiran, Tobias Max Philipp Hartwich, et al.
International Journal of Molecular Sciences|September 27, 2025
Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase InhibitorCem Demirkiran, Stefania Bellone, Victoria M Ettorre, et al.
Gynecologic Oncology Reports|May 7, 2026
Real World Outcomes of Pembrolizumab and Reduced-Dose Lenvatinib in Recurrent Endometrial Cancer by Platinum and p53 StatusAlexa Dzienny, Yasmin Abozenah, James Griffith, et al.
Gynecologic Oncology Reports|November 18, 2020
Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based studyEmily M Webster, Ghanshyam S Yadav, Stefan Gysler, et al.
Gynecologic Oncology|January 27, 2023
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivoChanhee Han, Blair McNamara, Stefania Bellone, et al.
Gynecologic Oncology|January 7, 2023
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expressionDennis Mauricio, Stefania Bellone, Levent Mutlu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2024
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)Sangini S Sheth, Ji Eun Oh, Stefania Bellone, et al.
Clinical & Experimental Metastasis|June 22, 2024
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2Levent Mutlu, Blair McNamara, Stefania Bellone, et al.
Gynecologic Oncology|November 28, 2022
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcomaJustin Harold, Stefania Bellone, Diego D Manavella, et al.
Pageof 5